Here are four things to know:
1. The shares were sold at an average of $24 per share, for a total transaction value of $841,050.
2. Currently, Mr. Phalen owns a total of 91,733 shares.
3. Out of 18 analysts covering Boston Scientific, 14 rate it a “buy,” zero rate it “sell,” while four rate it “hold.”
4. The company has a market cap of $33.15 billion.
More articles on GI/endoscopy:
Surveillance endoscopy improves esophageal cancer outcomes in Barrett’s esophagus patients: 3 insights
Small bowel resection inpatient costs total $28.5k & 7 more statistics
Dr. Maxime Mahe wins 2016 AGA-Athena Troxel Blackburn Award: 4 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.